204 results about "Advanced Glycosylation End Products" patented technology

The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products.

Novel peptides are useful as antagonists of RAGE and may be used to treat cancer, inflammation, diabetes and arthritis through the administration of a therapeutically effective amount of the peptide to a subject in need thereof.

The invention discloses an application of coumarin with a structure of formula IA or formula IB in preparing formation inhibitors of AGEs. Coumarin compounds can be used for treating and preventing various chronic diseases caused by the formation and the crosslinking of the AGEs, can also be used for preparing cosmetics with epidermis and papillary dermis anti-aging and remodeling activities and/or anti-wrinkle activities for inhibiting the formation and the crosslinking of the AGEs, and can further be used for preparing chemical agents for preventing denaturation of protein in food.

The invention relates to methods for identifying compounds which affect cellular stress. In particular, the method relates to identifying compounds which inhibit protein advanced glycation end product formation, where the compounds are carbonyl scavengers which inhibit the formation. The assay involves combing the substance of interest with histone H1 and ADP-ribose, and then measuring fluorescence and protein cross linking. Various inhibitors ofprotein AGE glycation have been identified, using this assay.

Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.

The invention provides an immunological analytical method and devices for determination of the advanced glycosylation end products (AGEs), comprising a reagents for determining the AGEs, which comprises a displaying carrier suspension and the antigen or antibody immobilized on the surface of the said displaying carrier; and a test strip, comprising of: a base plate, and constitutive parts provided on the said base plate. After infusing the said reagent into the said test strip, the immunological reaction of the AGEs antigen or antibody can be determined based on the agglutination phenomenon or accompanied changes of absorbance or color and the presence or raised level of the AGEs in the diabetic patient can be known accordingly such that the practitioner can prevent the occurrence of the complications, or block further the progression of the complications at the earlier stage.

Control of blood glucose is a fundamental goal in the treatment of diabetes mellitus. Glycation of l-lysine can lower blood glucose and advanced glycation end product (AGE) free adducts can be excreted in the urine. Lysine, an inexpensive amino acid, can be administered orally or parentally, and can be incorporated into a stereocomplex matrix as a time released preparation. In patients who suffer from diabetes and concomitant renal insufficiency who cannot clear sufficient quantities of AGE free adducts enantiomeric mixtures of lysine will lower blood glucose and AGEs since d-lysine has been shown to decrease protein glycation and lower hemoglobin Alc. This invention is not intended to replace insulin or oral hypoglycemic agents but is does offer patients a low cost and probably safe complementary therapy for the treatment of diabetes mellitus. In addition to the treatment of diabetes and its complications, this invention could lower AGE burden and slow or ameliorate some of the consequences of aging.

The invention relates to a sealwort extract as well as a preparation method and a use thereof. The sealwort extract is prepared by use of a method comprising the steps of performing reduced-pressure reflux on an extract obtained by performing ethanol hot extraction on sealwort, thereby obtaining a total extract, adding distilled water to the total extract for suspending, extracting by use of isovolumetric petroleum ether, ethyl acetate and n-butyl alcohol orderly, and recovering the solvents under reduced pressure, thereby obtaining an ethyl acetate extract part; the sealwort extract has inhibition effect on AGEs (Advanced Glycation End Products), and thus can be further applied to preparing medicines for treating diabetes and complications thereof and has important clinical application value.

The present invention discloses a use of lotus procyanidin as an advanced glycosylation end product formation inhibitor. The drug composition adopting the lotus procyanidin as a main active component comprises the following nature active component extracts, by weight, 70-80% of lotus procyanidin, 10-20% of a synergist such as VE, VC, epigallocatechin gallate (EGCG), cysteine and other ??complexes, and 5-10% of other nature extracts such as a lotus leaf extract, a ginkgo leaf extract and the like. According to the present invention, a high performance liquid chromatography method is adopted to detect a methylglyoxal removing effect of the lotus procyanidin and the main structure unit thereof (catechin), wherein methylglyoxal is an important intermediate substance during an advanced glycosylation end product formation process; a high performance liquid chromatography/multi-stage mass spectrometry method is adopted to identify adducts of four catechin and methylglyoxal and adducts of nine lotus procyanidin and methylglyoxal; and results show that lotus procyanidin provides good inhibition effects for advanced glycosylation end product formation in simulated physiological environments and simulated food systems.

The invention discloses a method for detecting advanced glycation end products (AGEs) in main stream smoke of a cigarette. The method specifically comprises analysis and determination of carboxy methyl lysine (CML) and carboxyethyl lysine (CEL). The method comprises the following steps: trapping total particulate matter of cigarette smoke by virtue of a Cambridge filter; carrying out ultrasonic extraction on the filter with a hydrochloric acid solution; and carrying out analysis by combining a cation exchange solid-phase extraction column purification method with liquid chromatogram-tandem mass spectrometry (LC-MS/MS). The method has the characteristics that (1) a detection method for AGEs in the main stream smoke of the cigarette is built for the first time; (2) a sample pretreatment method is built according to the characteristics of cigarette smoke sample matrix, derivative reaction is not required, and the pretreatment is simple and efficient; and (3) the method is high in sensitivity, good in qualitative accuracy and suitable for analysis of large batches of samples.

Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to treat glycogen storage diseases, including Fanconi's syndrome, as well as other pathological conditions resulting from the formation of AGE-proteins.

The invention discloses a detection method of a peptide-advanced glycation end product. The detection method is characterized by comprising the following steps: (1) removing a dicarbonyl compound in a liquid sample; (2) removing impurities and gathering the peptide-advanced glycation end product in the sample by using a solid-phase extraction technique; (3) determining the nature of the gathered peptide-advanced glycation end product; (4) carrying out enzymolysis on the gathered peptide-advanced glycation end product by using peptidase, removing the peptidase by using a filter membrane to obtain free peptide-advanced glycation end product; (5) quantitatively analyzing the free peptide-advanced glycation end product through mass spectrometric analysis. The method is capable of detecting the peptide-advanced glycation end product at a high flux and lowering the complexity of the quantitative detection of the peptide-advanced glycation end product; meanwhile, according to the method, the detection limit is relatively good, the linear relation between a concentration of a target product and a peak area of a signal is good, and the quantitative effect is good.

A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis.

The invention relates to a liquid-phase chip kit for acute coronary syndrome and a preparation method for the same. A liquid-phase chip mainly comprises microspheres coated with oxidized low density lipoprotein (ox-LDL), soluble CD40 ligand (sCD40L), matrix metallopeptidase 9 (MMP-9), tissue factor (TF), omentin and endogenous secretory receptor of advanced glycation end products (esRAGE) capture antibody respectively, detection antibodies labelled by biotin, and streptavidin phycoerythrin. The liquid-phase chip provided by the invention has the advantages of being high in detection efficiency, low in the quantity of the needed samples, strong in specificity, high in sensitivity, rapid and accurate in detection, and the like. Simultaneously, the chip reflects a protective factor level and an injury factor level in an organism, so that the risk stratification and prognosis conditions of a patient can be much comprehensively assessed. Simultaneously, the preparation method disclosed by the invention is simple and practicable, and good in stability, various process parameters such as the quantities of the microspheres and the antibodies, and the reaction process in the technical scheme of the preparation method are obtained on the basis of lots of experiments, and are the optimal parameter values of the preparation process.

A composition comprising cartilage extract, grape seed extract and tomato extract was found to have remarkable anti-oxidant effect and free-radical inhibition. The tomato extract comprises lycopene. The composition which comprises a hydrophilic antioxidant, a lipophilic (hydrophobic) antioxidant, and a cartilage extract dramatically increases collagen synthesis in the dermis. Furthermore, the composition lowers collagenase activity and levels of advanced glycation end products (AGE). The signs of ageing, such as photoageing due to exposure to UV radiation, are related to the levels of collagen syntheses and free-radical oxidation. Compositions of the invention are intended for the treatment of ageing skin and the delaying of the onset of the signs of ageing in healthy skin.

The invention discloses a class-I carboxymethyl lysine removing agent and application thereof. The removing agent is a quinones substance formed by the oxidization of polyphenol containing a catechol or pyrogallol structure unit. The removing agent is applied to the reduction of the content of carboxymethyl lysine in a food system. The quinones substance has stronger capability of removing AGEs (Advanced Glycation End Products) in the food system of which the pH is neutral or alkaline, and when the quinones substance is added after the food system generates the CML or before the CML is generated, the level of the CML in the system can be effectively reduced.